This updated statement summary on Haemophilus influenzae type b conjugate vaccines includes recommendations for use of a newly licensed Haemophilus conjugate vaccine, and a newly licensed combination vaccine that combines one of the Haemophilus conjugate vaccines and diphtheria and tetanus toxoids, and pertussis (DTP). The statement also includes revised guidelines for the use of all conjugate vaccines. The changes concern use of different vaccine products in children less than 15 months of age; timing for booster doses for completion of the immunization schedule in children 12 months of age and older; schedules for children in whom vaccination has been delayed in initiation, or has lapsed; choice of vaccine in children in whom vaccination against DTP or diphtheria and tetanus toxoids (DT) is deferred; number of doses for children with immunologic impairment associated with increased risk of H influenzae type b disease; and indications for rifampin prophylaxis in households where contacts have been vaccinated.

This content is only available via PDF.